|
Prevention of Coronary Aneurysms in Kawasaki Syndrome Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Prevention of Coronary Aneurysms in Kawasaki Syndrome conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Prevention of Coronary Aneurysms in Kawasaki Syndrome Clinical research trials and Prevention of Coronary Aneurysms in Kawasaki Syndrome health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Prevention of Coronary Aneurysms in Kawasaki Syndrome. Prevention of Coronary Aneurysms in Kawasaki Syndrome Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Prevention of Coronary Aneurysms in Kawasaki Syndrome clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Prevention of Coronary Aneurysms in Kawasaki Syndrome condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prevention of Coronary Aneurysms in Kawasaki Syndrome  Prevention of Coronary Aneurysms in Kawasaki Syndrome
Prevention of Coronary Aneurysms in Kawasaki Syndrome
For Condition: Cardiovascular Diseases,Coronary Aneurysm,Heart Diseases,Mucocutaneous Lymph Node Syndrome
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To test the efficacy of intravenous gamma globulin (IVGG) in preventing coronary artery aneurysms in children with Kawasaki Syndrome.
Details: BACKGROUND: Kawasaki Syndrome is an acute febrile illness that occurs predominantly in previously healthy young children. It is of unknown etiology and was first described in Japan in 1967. The illness carries an acute mortality rate of approximately 3 percent. The Centers for Disease Control defines Kawasaki Syndrome as a fever lasting five or more days for which no explanation can be found. Patients also must have at least four of the following symptoms: bilateral conjunctival infection; infected or fissured lips, pharynx, or a 'strawberry tongue'; erythema of the palms or soles, or edema of the hands or feet, or generalized or periungual desquamation; rash; and cervical lymphadenopathy. Coronary artery aneurysms occur in 15-20 percent of children with the illness. In the past, no treatment had been shown to be effective in preventing this complication. Investigators in Japan began to use IVGG to reduce the aneurysm formation. Preliminary results showing the usefulness of this therapy led to a multicenter trial in Japan in which 400 mg/kg/day of IVGG were given for five days to children also receiving aspirin for the condition. Results of the Japanese trial showed that within 29 days of the onset of the disease, coronary artery dilatation had developed in 42 percent of the aspirin-treated children and in 15 percent of the IVGG and aspirin-treated children. DESIGN NARRATIVE: Phase I was randomized, unblinded and stratified by age, sex, and center. Subjects were randomized to receive either 80 to 120 mg/kg/day of aspirin through day 14 of illness, subsequently reduced to 3 to 5 mg/kg/day as a single daily dose or to 400 mg/kg/day of intravenous gamma globulin for four consecutive days plus aspirin as above. Primary endpoint was formation of aneurysms as demonstrated by echocardiograms. Follow-up was for 7 weeks. Phase II of the trial began enrollment of 549 patients in May 1986 and ended enrollment in November 1989. Two hundred and seventy six children were randomized to receive 400 mg/kg of intravenous gamma globulin over four consecutive days. Two hundred and seventy-three received a single infusion of 2 g/kg of body weight over 10 hours. Both treatment groups received 100 mg/kg of aspirin per day through day 14 and then 3 to 5 mg/kg per day. The primary outcome variables were the presence or absence of coronary artery abnormalities evident at the two week and seven week follow-up examinations. Echocardiograms were obtained for 523 children at the two week visit and for 520 children at the seven week visit.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Parallel Assignment
Minimum Age/Maximum Age: 1 Year/17 Years
Genders: Both
Protocol Entry Criteria: Boys and girls who met the CDC criteria for Kawasaki Syndrome. Subjects were excluded if they presented themselves to the participating centers after the tenth day of illness.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
FredRosen, , Children's Hospital
Additional Information:
Study ID Numbers: 39;
Study Start Date: July 1985
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000520
Other Heart Diseases Studies:
1. Epidemiological Tool To Detect Angina Pectoris in Blacks
2. Family Based Interventions: Preschool Children and Parent
3. High Blood Pressure in the Young
4. Effect of pravastatin on endothelial dysfunction following a single high fat meal
5. Inflammation Markers Over Time in Cardiovascular Disease
Related Studies:
Other Heart Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Prevention of Coronary Aneurysms in Kawasaki Syndrome
|
|
|
|
|
|
|
|
